Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 52.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 31,470 shares of the biotechnology company’s stock after acquiring an additional 10,774 shares during the period. Dimensional Fund Advisors LP’s holdings in Oramed Pharmaceuticals were worth $81,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC purchased a new position in shares of Oramed Pharmaceuticals in the 1st quarter worth $68,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Stock Down 1.3 %

Shares of Oramed Pharmaceuticals stock opened at $2.35 on Wednesday. The firm has a market cap of $95.48 million, a P/E ratio of 9.04 and a beta of 1.77. Oramed Pharmaceuticals Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $3.67. The business has a 50-day moving average price of $2.39 and a 200 day moving average price of $2.40.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.21. As a group, equities research analysts anticipate that Oramed Pharmaceuticals Inc. will post 0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ORMP shares. StockNews.com lowered Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.